Axithra

Rapid Drug Monitoring at the Point of Need

Ghent, Belgium · $11.7M raised

Headquarters
Ghent
Employees
1–10
Business Model
B2B
Total Funding
$11.7M
Last Round
$11.7M SeedSep 2023
Rounds
1

Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.

About

Axithra is a Belgian medtech company spun out of the Photonics Research Group at Ghent University and the Interuniversity Microelectronics Centre (imec). The company is developing a rapid, point-of-care therapeutic drug monitoring (TDM) platform based on proprietary optics and photonics technology. Its system is designed to quickly and accurately measure drug concentrations in blood at the bedside, enabling clinicians to personalize treatment in real time rather than waiting for centralized lab results. The lead application targets personalization of β-lactam antibiotic therapy in intensive care units — a setting where dosing precision is critical to preventing toxicity and drug resistance. Unlike incumbent methods such as mass spectrometry or immunoassays, Axithra's photonics-on-chip approach aims to be faster, lower-cost, and deployable at the point of need. In 2026, the company launched its first external clinical evaluation in collaboration with UZ Gent and received funding through Belgium's health innovation program. The company is based in Ghent, Belgium.

Summary

Axithra is a Biotech company based in Ghent, Belgium. It has raised $11.7M in total across 1 round, most recently a $11.7M Seed round in Sep 2023. Investors include IMEC XPand, Kurma Partners and Qbic Fund.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

SeedSeed RoundSep 2023
$11.7M

Investors

Similar Companies

Pharmaceutical Product Development, Inc. (PPD)Acquired

Global contract research organization providing comprehensive drug development and laboratory ser...

Wilmington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.9BJan 2019
Warner ChilcottAcquired

Specialty pharmaceutical company

Rockaway, United States1001–5000Biotech, Healthcare
Private EquityTotal funding$3.0BJan 2004
Altos Labs

Altos Labs combines academic science and industry development to create medicines that restore ce...

San Francisco, United States501–1000Life Sciences, Biotech
Series ATotal funding$3.0BJan 2022
Syneos HealthAcquired

Integrated biopharmaceutical solutions company

Burlington, United States10001+Biotech, Healthcare
Private EquityTotal funding$3.0BMay 2017
BeiGeneIPO

BeOne Medicines develops transformative oncology medicines through rigorous science, an accelerat...

Cambridge, United States10001+Biotech, Oncology
Corporate RoundTotal funding$2.8BJan 2020
BridgeBioIPO

BridgeBio develops treatments for genetic conditions through autonomous condition-focused teams s...

San Francisco Bay Area, United States201–500Biotech, Healthcare
Growth EquityTotal funding$2.7BJul 2026

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

Axithra on Indexed.vc
<a href="https://indexed.vc/companies/axithra"><img src="https://indexed.vc/api/badge/company/axithra" alt="Axithra on Indexed.vc" width="260" height="76" /></a>